Search
Chlormerodrin
go.drugbank.com/drugs/DB00534ApprovedWithdrawnThe radiolabeled form has been used as a diagnostic and research tool. It is no longer used and has been replaced with new classes of diuretic drugs.
NOX-700
go.drugbank.com/drugs/DB05464ExperimentalNOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … It has since been found that oxidative signaling of the redox-sensitive transcription factor, NF-κB, and inhibiting protein glycation are responsible for the drug's therapeutic effects.
Calcifediol
go.drugbank.com/drugs/DB00146ApprovedInvestigationalNutraceuticalThe major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and no...
AP5280
go.drugbank.com/drugs/DB05112ExperimentalAP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Ibudilast
go.drugbank.com/drugs/DB05266Investigational(codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or
Categories: Drugs for Obstructive Airway DiseasesMK-212
go.drugbank.com/drugs/DB12111InvestigationalMK-212 has been used in trials studying the treatment of Alcoholism.
Salts: MK-212 hydrochlorideTetrabenazine
go.drugbank.com/drugs/DB04844ApprovedA drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. ...
ATHX-105
go.drugbank.com/drugs/DB06008InvestigationalATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.
Eplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigationalIt was previously investigated as a potential treatment for hereditary transthyretin-mediated amyloidosis. … Eplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery.
2-ethylhexyl benzoate
go.drugbank.com/drugs/DB11291ApprovedWithdrawnMixtures: UV Capture Vita Sun Gel, UV Capture Sebum Control Sun Cream